Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Lilly’s tirzepatide bests semaglutide in type 2 diabetes trial 

By Brian Buntz | June 25, 2021

Eli LillyEli Lilly (NYSE:LLY) has announced that its investigational drug tirzepatide led to more substantial blood glucose and body weight improvements in a Phase 3 trial than semaglutide, a diabetes drug from Novo Nordisk (NYSE:NVO) that recently scored FDA approval for weight loss in early June.

Lilly’s SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes.

A JAMA opinion article recently posited that semaglutide could lead to a ‘new dawn’ for obesity treatment.

The Lilly trial randomly assigned patients to receive tirzepatide at doses of 5 mg, 10 mg, or 15 mg or a 1-mg dose of semaglutide.

Semaglutide is a glucagon-like peptide 1 receptor agonist. Conversely, tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

In the 40-week SURPASS-2 trial, investigators tested three doses of tirzepatide (5, 10 and 15 mg) and compared the findings to semaglutide data. All three were superior for tirzepatide.

The hemoglobin A1C reductions were as follows:

  • A 5 mg dose led to a 2.09% reduction.
  • A 10 mg dose led to a 2.37% reduction.
  • A 15 mg dose led to a 2.46% reduction.
  • A 1 mg dose of semaglutide led to a 1.86% reduction.

Weight reductions were as follows:

  • A 5 mg led to a reduction of 7.8 kg (17.2 lbs.) or –8.5% of total body weight.
  • A 10 mg led to a reduction of 10.3 kg (22.7 lbs.) or –11.0% of total body weight.
  • A 15 mg led to a reduction of 12.4 kg (27.3 lbs.) or –13.1% of total body weight.
  • Semaglutide led to a 6.2 kg (13.7 lbs.) weight reduction or –6.7% of total body weight.

The safety profile for tirzepatide was similar to that of semaglutide in the trial. The most frequent adverse events in the trial were gastrointestinal and were generally mild to moderate.

Assuming tirzepatide wins approval, it could offer significant potential to people with type 2 diabetes.


Filed Under: clinical trials, Drug Discovery
Tagged With: Eli Lilly, Eli Lilly & Co., Lilly, Novo Nordisk, semaglutide, SURPASS-2, Tirzepatide
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50